PARIS, France, Sep 17, 2019 – Eligo Bioscience SA, a biotechnology company developing next-generation precision medicines for microbiome engineering, today announced the expansion of the Company’s executive management team and development team. Aurélie Grienenberger, PhD, has been appointed Chief Business Officer and Olivier Kerbarh, PhD, has been appointed Senior Manager CMC.
“We are tremendously excited to add these two deeply experienced individuals to our growing team at Eligo Bioscience at a time when we are moving our lead program towards the clinic.”, said Xavier Duportet, co-founder and CEO at Eligo Bioscience. “We look forward to their unique and comprehensive expertise as we grow the organization to best position our programs for the clinic and pursue strategic opportunities to strengthen our pipeline. Their collective experience will be invaluable as we execute on our strategy to discover and develop next-wave microbiome precision medicines for patients with diseases for which limited treatment options currently exist.”
Aurélie Grienenberger brings substantial experience in business development and drug development. She joins Eligo from Sanofi Global Business Development, where her focus was on executing collaboration and licensing deals to support Sanofi R&D pipeline across immunology, rare diseases, metabolic diseases, vaccines and infectious diseases. In particular, she was deeply involved in the strategic transaction with Evotec to accelerate Infectious Diseases R&D. Previously, Aurelie acquired strategic and operational R&D expertise in biotech and pharma, over 15+ years. She held Development and Regulatory leadership positions, supporting programs ranging from Phase 1 to FDA approval at Dyax Corp. and Fovea Pharmaceuticals, and served as Chief of Staff to the President of R&D at Sanofi. Aurélie holds an engineering degree from Ecole Polytechnique with a major in Chemistry and Biology, a PhD from the University of Marseilles in genetics and molecular biology, and a Business Master from London Business School.